Health tech PR is the communications work that helps digital health, telehealth, clinical AI, and medical device companies earn trust from patients, clinicians, and health system buyers while staying inside HIPAA, FDA, and FTC rules. The programs that work clear every claim through medical and regulatory review first, then pitch consumer and clinical trade press separately.
What Is Health Tech PR and Who Does It Need to Reach?
Health tech PR covers communications strategy for digital health companies, telemedicine platforms, healthcare AI, medical devices, diagnostic tools, EHR vendors, payer technology, digital therapeutics, and remote patient monitoring.
The audiences fall into three groups: consumers choosing a service, clinicians evaluating a tool, and institutions (health systems, payers, employers, and regulators) making procurement and policy decisions. A program has to reach all three without overpromising clinical outcomes or breaking FDA labeling, HIPAA disclosure, or state corporate-practice-of-medicine rules.
The press splits into four pools. Consumer health and wellness press includes Wall Street Journal Health, NPR Health, and the lifestyle desks of major outlets. Clinical trade press includes Modern Healthcare, Becker's, Fierce Healthcare, MedCity News, and HealthIT News. Biopharma and life sciences press includes STAT News, Endpoints, and Fierce Biotech. Financial press covers public and pre-IPO health tech companies.
A program that targets only one of these pools reaches only one of the audiences that decide health tech outcomes.
Which Rules and Pressures Shape Health Tech Communications?
Four pressures shape every health tech communications program: regulation, clinical credibility, multiple audiences, and sales-cycle length.
| Pressure |
What it demands |
| Regulatory |
Claims must clear FDA marketing guidance, HIPAA disclosure rules, FTC substantiation standards, state telehealth licensure, and SEC Regulation FD (for public and pre-IPO companies) before publication. |
| Clinical credibility |
Everything-PR's editorial framework ranks evidence in this order: peer-reviewed research, white papers, case studies, testimonials, then executive-quote press releases. Programs that skip levels get discounted by clinical and institutional audiences. |
| Multiple audiences |
Patients, providers, payers, employers, regulators, and investors each use different evidence standards, press pools, and conferences. |
| Sales cycle |
Consumer decisions take days. Purchases by health systems, payers, and employers take quarters, so a program has to support both rhythms without bending the message. |
Patient stories are the most compelling health tech content and the most regulated. Sharing identifiable patient information requires documented HIPAA authorization, and testimonials need informed consent and FTC-compliant disclosures. Most programs reduce that burden by using deidentified or aggregate data, patients who have already left care, or clinician voices.
Clinical claims need substantiation that holds up to FDA scrutiny whenever the product is FDA-regulated and the claim concerns intended use, safety, efficacy, or comparative performance. Any substantive clinical claim should go through medical, regulatory, and legal review before it is published.
What Has Changed in Health Tech Communications Since 2024?
Weight loss drugs, public-market listings, and FDA software guidance have each changed what health tech companies must explain publicly since 2024.
Hims & Hers announced GLP-1 injections for its weight loss program on May 20, 2024, with compounded injections starting at $199 a month, according to its company press release. Telehealth rival Ro had launched its weight loss program with GLP-1 medications in January 2023, according to Earnest Analytics. On its fourth-quarter 2024 earnings call, Hims & Hers said compounded semaglutide would likely not be offered after the first quarter, after the FDA declared the semaglutide shortage resolved, CNBC reported. Brands selling weight loss treatments should state plainly which products are FDA-approved and which are compounded.
Tempus AI began trading on Nasdaq under the ticker TEM on June 14, 2024, after pricing its initial public offering at $37 per share, according to the company's announcement. Public-company status puts every clinical claim in front of investors as well as clinicians.
FDA digital health guidance now covers software as a medical device, clinical decision support, AI-enabled device software, and predetermined change control plans. Launch communications for these products need regulatory review before the announcement, not after it. A vendor announcing a clinical AI tool should state what data trained it, which populations validated it, and what it does not do, because clinicians and procurement teams evaluate those points.
Which Brands Show Health Tech PR Done Well?
Five brands show the range of health tech communications: Hims & Hers, Teladoc Health, Calm, Whoop, and Tempus AI.
| Brand |
Category |
What its communications show |
| Hims & Hers |
NYSE: HIMS, direct-to-consumer telehealth |
Runs consumer marketing and public-company investor communications side by side, and had to explain GLP-1 weight loss products under FDA prescription marketing, FTC substantiation, and state licensure rules after its May 20, 2024 launch. |
| Teladoc Health |
NYSE: TDOC, virtual care |
Speaks to consumers through BetterHelp, to employers through its Livongo legacy, and to enterprises through virtual care, and has to keep its positioning consistent across all three. |
| Calm |
Consumer mindfulness app |
Raised $75 million at a $2 billion valuation in December 2020, according to Bloomberg. Presents itself as mindfulness, not medicine, and draws press attention with celebrity-narrated Sleep Stories, including narration from LeBron James and Matthew McConaughey. |
| Whoop |
Performance wearable |
Announced a $575 million Series G at a $10.1 billion valuation on March 31, 2026, with athletes including Cristiano Ronaldo and LeBron James among its investors. HLTH reported on April 1, 2026 that the company faced regulatory scrutiny tied to its BPI feature, which shows how close a wellness brand can sit to the medical-device line. |
| Tempus AI |
NASDAQ: TEM, clinical AI |
Began trading on June 14, 2024 after pricing at $37 per share. Its oncology and genomics claims face peer-review expectations, FDA software as a medical device rules, and public-company scrutiny at the same time. |
Consumer telehealth. Hims & Hers and Ro work under the same regulatory frame of state telehealth licensure, FDA prescription marketing rules, and FTC substantiation, with different voices. Hims & Hers markets at consumer scale, while Ro leans on clinical-care positioning. Everything-PR analyzes the playbook in Hims, Ro, and telehealth drug marketing.
Mental health platforms. Calm and Headspace keep clinical-claim language tightly bounded as consumer mindfulness brands. BetterHelp (Teladoc) and Talkspace run clinical online therapy with provider networks and HIPAA-grade infrastructure. Mindfulness brands work in lifestyle and wellness press, and therapy platforms work in clinical and health-policy press.
Clinical AI and digital care. Tempus AI, Hinge Health (musculoskeletal care), and Maven Clinic (women's health) face the most demanding evidence requirements: peer-reviewed publication, validated clinical endpoints, and FDA pathway planning for software as a medical device. Everything-PR also covers telehealth as an enterprise SaaS platform.
What Do the Strongest Health Tech PR Programs Share?
The strongest health tech PR programs share seven practices.
- Medical, regulatory, and communications reviewers sit together, so claims clear review in days instead of weeks.
- Consumer health press and clinical trade press get separate angles, cadences, and spokespeople.
- Original data, peer-reviewed where possible, backs the claims, because institutional buyers discount marketing claims without evidence.
- Executives speak and program content at HIMSS, HLTH, ViVE, the JPMorgan Healthcare Conference, and the relevant clinical society meetings.
- Credible physician and clinician advocates carry messages alongside executives.
- Analyst relations with KLAS, Gartner, Forrester, Chilmark, and Frost & Sullivan runs as a multi-year program, not a quarterly campaign.
- The communications function can speak to both consumer and institutional audiences without switching tone clumsily.
How Does a Health Tech Crisis Differ From Other Crises?
A health tech crisis runs on mandatory regulatory clocks that most business crises do not have. Under the HHS Breach Notification Rule, covered entities must notify affected individuals without unreasonable delay and no later than 60 days after discovering a breach of unsecured protected health information. State notification laws add their own deadlines, and the HHS Office for Civil Rights enforces HIPAA.
Adverse events trigger FDA reporting, including through the MAUDE database, and device recalls follow FDA Class I, II, and III classifications with different urgency. Errors in AI-enabled tools attract regulator attention as well, so the response has to address bias, validation, and remediation directly. Regulators and press frame these events around patient harm, and communications that put the company ahead of the patient tend to backfire. See Everything-PR's crisis communications coverage.
How Should a Company Choose a Health Tech PR Agency?
A company choosing a health tech PR agency should test for three things: regulatory literacy, clinical depth, and range across consumer and institutional audiences.
Regulatory literacy means the team can read an FDA guidance document and has done so in the last 60 days. Clinical depth means the agency understands how providers evaluate tools and has clinicians or clinical advisors on staff. Range means the agency can work with both consumer and institutional audiences, because an agency that knows only one delivers half the work a serious health tech company needs.
Everything-PR ranks firms by specialty in its guide to the best healthcare PR agencies. Related coverage includes What Is Biotech PR and the healthcare PR overview.
What Does Everything-PR Research Show on Health and Wellness AI?
Everything-PR publishes an AI Visibility Index series for Health and Wellness that ranks the brands AI engines cite in consumer health discovery against the brands that lose ground in AI answers.
The featured study is The Wellness AI Citation Share Study, which covers 28 brands across supplements, functional beverages, connected fitness, wearables, mental wellness, and recovery tech, ranked on the locked Citation Share methodology. AG1 leads at 100, Oura is second at 86, and Whoop is third at 78. For hospitals, doctors, and medical brands, see GEO for healthcare.
Read Next
The Wellness AI Citation Share Study · Healthcare PR · What Is Biotech PR · Pharma · Wellness · Crisis Communications · Generative Engine Optimization
